Peptide Regulatory Status
Peptides fall into four regulatory buckets: approved medicines, investigational drugs in a sponsored trial, lawful ingredients in a specific market, and compounds with no approved human use anywhere. Most of what circulates in the wellness trade sits in the fourth bucket.
The four buckets
Approved medicines carry an authorization from a named regulator for a named indication, and their labels govern use. Investigational peptides may be administered only in a trial under an authorized application, with ethics approval and informed consent. A small number of peptide-derived ingredients are lawful in cosmetics or supplements in defined markets at defined concentrations. Everything else is an unapproved compound. Selling such a compound with a human-use claim is a breach of drug law in every major jurisdiction, and the not for human consumption label is a warning, not a permission.
Compounding is not a general route
In the United States, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act allow pharmacies and outsourcing facilities to compound with bulk substances under specific conditions. FDA maintains a list of bulk substances that may present significant safety risks, which currently includes items such as kisspeptin-10 for 503A and several growth hormone secretagogue peptides for 503B, and the list is revised through Pharmacy Compounding Advisory Committee review. Because entries are added and removed, the current published list governs, and no page on this site should be read as a snapshot of it.
Why status drives the delivery question
Regulatory status sets what a formulation program can lawfully produce. For an approved peptide, the sponsor may pursue a reformulation with a defined regulatory path. For an investigational compound, the work belongs inside a trial-supporting development agreement. For an unapproved compound, the honest answer is that no consumer product can be made, and the only legitimate work is preclinical research by a qualified sponsor. Vegalab applies that filter before scoping any peptide project.
What Vegalab does and does not supply
Vegalab supplies encapsulation and formulation development. It does not sell peptides, does not act as a peptide source, does not provide dosing, reconstitution or administration guidance, and does not support resale of research-grade material for human use. Partners bring their own compound with documented provenance and their own regulatory standing. Provenance means a certificate of analysis, a named manufacturer and a documented chain of custody. Where a partner cannot supply those, the project does not start, because neither formulation data nor a stability file means anything on material of unknown identity.
Key facts
- Distribution of an unapproved new drug for human use is prohibited in the US (21 U.S.C. 331, 355)
- FDA lists certain bulk drug substances, including several peptides such as kisspeptin-10, as presenting significant safety risks in compounding, and the list is revised over time (FDA, Certain Bulk Drug Substances for Use in Compounding, current revision)
- Pharmacy Compounding Advisory Committee review can move substances on and off the interim bulks categories, so status changes over time (FDA, 503A interim bulks list)
- Investigational human use requires an authorized clinical trial application and ethics approval (21 CFR 312; EU Regulation 536/2014)
How our delivery technology applies
Peptides fail on protease exposure, short circulating half-life and low epithelial permeability. Multi-layer encapsulation addresses the first two in principle, through protease-excluding inner matrices and controlled release that flattens a peak, and can add mucoadhesion for residence time. Permeability remains the limiting term. We scope peptide work as a research program for a qualified sponsor, never as a consumer formulation.
Sponsors with documented regulatory standing can request a peptide feasibility scope.
Related reading
Last updated: